Novartis, Astellas Intend To Disprove Eczema Treatments’ Cancer Risk
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis and Astellas aim to use ongoing studies to convince FDA to remove a requirement for a "black box" warning of potential cancer risk in labeling for their topical calcineurin inhibitors